Trials / Completed

CompletedNCT06971198

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 26 (actual)

Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Industry
Sex: All
Age: 18 Years – 45 Years
Healthy volunteers: Accepted

Summary

To evaluate the safety, tolerability and pharmacokinetic characteristics of HSK39004 dry powder inhalation in healthy subjects.

Conditions

Healthy Volunteers

Interventions

Type	Name	Description
DRUG	HSK39004	0.75\~4mg
DRUG	Placebo	0.75\~4mg

Timeline

Start date: 2025-02-10
Primary completion: 2025-03-28
Completion: 2025-05-06
First posted: 2025-05-14
Last updated: 2025-05-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06971198. Inclusion in this directory is not an endorsement.

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder I (NCT06971198) · Clinical Trials Directory